<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">oncotomsk</journal-id><journal-title-group><journal-title xml:lang="ru">Сибирский онкологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Siberian journal of oncology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1814-4861</issn><issn pub-type="epub">2312-3168</issn><publisher><publisher-name>Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21294/1814-4861-2023-22-1-95-100</article-id><article-id custom-type="elpub" pub-id-type="custom">oncotomsk-2435</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЛАБОРАТОРНЫЕ И ЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>LABORATORY AND EXPERIMENTAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Повышение активности ферментов пуринового обмена как один из факторов патогенеза злокачественных новообразований прямой кишки</article-title><trans-title-group xml:lang="en"><trans-title>Increased activity of enzymes involved in purine metabolism as one of the factors of rectal cancer pathogenesis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9217-8727</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зуйков</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Zuikov</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Зуйков Сергей Александрович, кандидат биологических наук, доцент кафедры биологической химии</p><p>83003, г. Донецк, пр. Ильича, 16, Донецкая Народная Республика</p><p>SPIN-код: 1307-2565,</p><p>Author ID (Scopus): 56247064300</p></bio><bio xml:lang="en"><p>Sergei A. Zuikov, PhD, Associate Professor of the Department of Biological Chemistry</p><p>16, Ilyich Ave., 83003, Donetsk, Donetsk People's Republic</p><p>Author ID (Scopus): 56247064300</p></bio><email xlink:type="simple">83chem@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Полунин</surname><given-names>Г. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Polunin</surname><given-names>G. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Полунин Герман Евгеньевич, доктор медицинских наук, проректор по лечебной работе, профессор кафедры общей хирургии № 1</p><p>83003, г. Донецк, пр. Ильича, 16, Донецкая Народная Республика</p><p>Author ID (Scopus): 7006943768</p></bio><bio xml:lang="en"><p>German E. Polunin, MD, Vice-Rector for Medical Work, Professor of the Department of General Surgery No. 1</p><p>16, Ilyich Ave., 83003, Donetsk, Donetsk People's Republic</p><p>Author ID (Scopus): 7006943768</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГОО ВПО «Донецкий национальный медицинский университет им. М. Горького»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>M. Gorky Donetsk National Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>22</day><month>02</month><year>2023</year></pub-date><volume>22</volume><issue>1</issue><fpage>95</fpage><lpage>100</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Зуйков С.А., Полунин Г.Е., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Зуйков С.А., Полунин Г.Е.</copyright-holder><copyright-holder xml:lang="en">Zuikov S.A., Polunin G.E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.siboncoj.ru/jour/article/view/2435">https://www.siboncoj.ru/jour/article/view/2435</self-uri><abstract><p>Цель исследования ‒ изучить изменения активностей ферментов распада пуриновых нуклеозидов – аденозиндезаминазы (АДА) и ксантиноксидазы (КО) у больных раком прямой кишки (РПК).</p><sec><title>Материал и методы</title><p>Материал и методы. Исследование изучаемых показателей проводили в плазме крови и гомогенатах тканей: опухолевой ткани и нетрансформированной слизистой оболочке прямой кишки у 70 больных РПК I–IV стадии. Гистологической формой РПК являлась аденокарцинома. Показателем метаболизма пуриновых нуклеозидов послужило определение активностей ферментов АДА и КО. Методом исследования ферментативных активностей была спектрофотометрия.</p></sec><sec><title>Результаты</title><p>Результаты. У больных РПК в плазме крови установлено статистически значимое повышение активностей ферментов катаболизма пуринов АДА и КО по сравнению со здоровыми людьми. Также установлено достоверное повышение активностей АДА и КО в ткани опухоли относительно нетрансформированной ткани. Выявлены взаимосвязи между активностями ферментов катаболизма пуринов в плазме крови и в тканях. Обнаружено повышение катаболизма пуринов в зависимости от стадии РПК.</p></sec><sec><title>Выводы</title><p>Выводы. Установленное повышение активностей АДА и КО свидетельствует об усилении катаболизма пуринов не только при злокачественной трансформации, но и при опухолевой прогрессии, что, в свою очередь, носит системный характер.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim: to study changes in the activities of purine nucleotide degradation enzymes – adenosine deaminase (ADA) and xanthine oxidase (XO) in patients with rectum cancer (RC).</p></sec><sec><title>Material and Methods</title><p>Material and Methods. The activity of purine nucleotide degradation enzymes was studied in blood plasma and tissue homogenates: tumor tissue and normal rectal mucosa in 70 patients with stage I–IV RC. The histological type of RC was adenocarcinoma. The levels of ADA and XO activities were measured using spectrophotometry.</p></sec><sec><title>Results</title><p>Results. The activity of ADA and XO in blood serum of RC patients was significantly higher than that of healthy people. A significant increase in the activity of ADA and XO in tumor tissue compared to normal tissue was also found. The relationship between the activities of the enzymes of purine catabolism in blood plasma and tissues were revealed. An increase in purine catabolism depending on the stage of RC was found.</p></sec><sec><title>Conclusion</title><p>Conclusion. The increased ADA and XO activities indicated the enhanced purine catabolism not only in malignant transformation, but also in tumor progression.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>аденозиндезаминаза</kwd><kwd>ксантиноксидаза</kwd><kwd>пуриновый обмен</kwd><kwd>рак прямой кишки</kwd><kwd>плазма крови</kwd><kwd>гомогенат тканей</kwd></kwd-group><kwd-group xml:lang="en"><kwd>adenosine deaminase</kwd><kwd>xanthine oxidase</kwd><kwd>purine metabolism</kwd><kwd>rectum cancer</kwd><kwd>blood plasma</kwd><kwd>tissue homogenate</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Каприн А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). М., 2020. 252 с.</mixed-citation><mixed-citation xml:lang="en">Kaprin A.D., Starinsky V.V., Shakhzadova A.O. Cancer incidence and mortality in Russia in 2019. Moscow, 2020. 252 p. (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Рак. Всемирная организация здравоохранения URL: https://www.who.int/ru/news-room/fact-sheets/detail/cancer. [cited 2022 Apr 1].</mixed-citation><mixed-citation xml:lang="en">Cancer. World Health Organization (in Russian)]. [Internet]. URL: https://www.who.int/ru/news-room/fact-sheets/detail/cancer. [cited 2022 Apr 1.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Дубовиченко Д.М., Вальков М.Ю., Мерабишвили В.М., Карпунов А.А., Щербаков А.М., Валькова Л.Е., Панкратьева А.Ю. Эпидемиологическая оценка выживаемости при раке прямой кишки: обзор литературы и собственное исследование. Вопросы онкологии. 2020; 66(1): 36–41. doi: 10.37469/0507-3758-2020-66-1-36-41.</mixed-citation><mixed-citation xml:lang="en">Dubovichenko D.M., Valkov M.Y., Merabishvili V.M., Karpunov A.A., Scherbakov A.M., Valkova L.E., Pankratyeva A.Y. Epidemiological characteristic of survival in rectal cancer: a literature review and the results of own research. Problems in Oncology. 2020; 66(1): 36–41. (in Russian). doi: 10.37469/0507-3758-2020-66-1-36-41.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Каприн А.Д., Гамеева Е.В., Поляков А.А., Корниецкая А.Л., Рубцова Н.А., Феденко А.А. Влияние пандемии COVID-19 на онкологическую практику. Сибирский онкологический журнал. 2020; 19(3): 5–22. doi: 10.21294/1814-4861-2020-19-3-5-22.</mixed-citation><mixed-citation xml:lang="en">Kaprin A.D., Gameeva E.V., Polyakov A.A., Kornietskaya A.L., Rubtsova N.A., Fedenko A.A. Impact of the COVID-19 pandemic on the oncological practice. Siberian Journal of Oncology. 2020; 19(3): 5–22. (in Russian). doi: 10.21294/1814-4861-2020-19-3-5-22.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1): 7–30. doi: 10.3322/caac.21590.</mixed-citation><mixed-citation xml:lang="en">Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1): 7–30. doi: 10.3322/caac.21590.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Camici M., Garcia-Gil M., Pesi R., Allegrini S., Tozzi M.G. PurineMetabolising Enzymes and Apoptosis in Cancer. Cancers (Basel). 2019; 11(9): 1354. doi: 10.3390/cancers11091354.</mixed-citation><mixed-citation xml:lang="en">Camici M., Garcia-Gil M., Pesi R., Allegrini S., Tozzi M.G. PurineMetabolising Enzymes and Apoptosis in Cancer. Cancers (Basel). 2019; 11(9): 1354. doi: 10.3390/cancers11091354.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Battelli M.G., Polito L., Bortolotti M., Bolognesi A. Xanthine oxidoreductase in cancer: more than a differentiation marker. Cancer Med. 2016; 5(3): 546–57. doi: 10.1002/cam4.601.</mixed-citation><mixed-citation xml:lang="en">Battelli M.G., Polito L., Bortolotti M., Bolognesi A. Xanthine oxidoreductase in cancer: more than a differentiation marker. Cancer Med. 2016; 5(3): 546–57. doi: 10.1002/cam4.601.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Wang L., Londono L.M., Cowell J., Saatci O., Aras M., Ersan P.G., Serra S., Pei H., Clift R., Zhao Q., Phan K.B., Huang L., LaBarre M.J., Li X., Shepard H.M., Deaglio S., Linden J., Thanos C.D., Sahin O., Cekic C. Targeting Adenosine with Adenosine Deaminase 2 to Inhibit Growth of Solid Tumors. Cancer Res. 2021; 81(12): 3319–32. doi: 10.1158/00085472.CAN-21-0340.</mixed-citation><mixed-citation xml:lang="en">Wang L., Londono L.M., Cowell J., Saatci O., Aras M., Ersan P.G., Serra S., Pei H., Clift R., Zhao Q., Phan K.B., Huang L., LaBarre M.J., Li X., Shepard H.M., Deaglio S., Linden J., Thanos C.D., Sahin O., Cekic C. Targeting Adenosine with Adenosine Deaminase 2 to Inhibit Growth of Solid Tumors. Cancer Res. 2021; 81(12): 3319–32. doi: 10.1158/00085472.CAN-21-0340.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Liu D., Yun Y., Yang D., Hu X., Dong X., Zhang N., Zhang L., Yin H., Duan W. What Is the Biological Function of Uric Acid? An Antioxidant for Neural Protection or a Biomarker for Cell Death. Disease Markers. 2019; 31: 1–9. doi: 10.1155/2019/4081962.</mixed-citation><mixed-citation xml:lang="en">Liu D., Yun Y., Yang D., Hu X., Dong X., Zhang N., Zhang L., Yin H., Duan W. What Is the Biological Function of Uric Acid? An Antioxidant for Neural Protection or a Biomarker for Cell Death. Disease Markers. 2019; 31: 1–9. doi: 10.1155/2019/4081962.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Allard B., Allard D., Buisseret L., Stagg J. The adenosine pathway in immuno-oncology. Nat Rev Clin Oncol. 2020; 17(10): 611–29. doi: 10.1038/s41571-020-0382-2. Epub 2020 Jun 8. Erratum in: Nat Rev Clin Oncol. 2020.</mixed-citation><mixed-citation xml:lang="en">Allard B., Allard D., Buisseret L., Stagg J. The adenosine pathway in immuno-oncology. Nat Rev Clin Oncol. 2020; 17(10): 611–29. doi: 10.1038/s41571-020-0382-2. Epub 2020 Jun 8. Erratum in: Nat Rev Clin Oncol. 2020.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Tritsch G.L. Validity of the continuous spectrophotometric assay of Kalckar for adenosine deaminase activity. Anal Biochem. 1983; 129(1): 207–9. doi: 10.1016/0003-2697(83)90070-2.</mixed-citation><mixed-citation xml:lang="en">Tritsch G.L. Validity of the continuous spectrophotometric assay of Kalckar for adenosine deaminase activity. Anal Biochem. 1983; 129(1): 207–9. doi: 10.1016/0003-2697(83)90070-2.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Карпищенко А.И., Алипов А.Н., Алексеев В.В. Медицинские лабораторные технологии: руководство по клинической лабораторной диагностике. М., 2013.</mixed-citation><mixed-citation xml:lang="en">Karpishchenko A.I., Alipov A.N., Alekseev V.V. Medical laboratory technologies: a guide to clinical laboratory diagnostics. Moscow, 2013. (in Russian)].</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 193(1): 265–75.</mixed-citation><mixed-citation xml:lang="en">Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 193(1): 265–75.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Kuo T., Kim-Muller J.Y., McGraw T.E., Accili D. Altered Plasma Profile of Antioxidant Proteins as an Early Correlate of Pancreatic β Cell Dysfunction. J Biol Chem. 2016; 291(18): 9648–56. doi: 10.1074/jbc.M115.702183.</mixed-citation><mixed-citation xml:lang="en">Kuo T., Kim-Muller J.Y., McGraw T.E., Accili D. Altered Plasma Profile of Antioxidant Proteins as an Early Correlate of Pancreatic β Cell Dysfunction. J Biol Chem. 2016; 291(18): 9648–56. doi: 10.1074/jbc.M115.702183.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Eisenstein A., Chitalia S.V., Ravid K. Bone Marrow and Adipose Tissue Adenosine Receptors Effect on Osteogenesis and Adipogenesis. Int J Mol Sci. 2020; 21(20): 7470. doi: 10.3390/ijms21207470.</mixed-citation><mixed-citation xml:lang="en">Eisenstein A., Chitalia S.V., Ravid K. Bone Marrow and Adipose Tissue Adenosine Receptors Effect on Osteogenesis and Adipogenesis. Int J Mol Sci. 2020; 21(20): 7470. doi: 10.3390/ijms21207470.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou R., Zhang S., Gu X., Ge Y., Zhong D., Zhou Y., Tang L., Liu X.L., Chen J.F. Adenosine A2A receptor antagonists act at the hyperoxic phase to confer protection against retinopathy. Molecular Medicine. 2018; 24(41): 1–13. doi: 10.1186/s10020-018-0038-1.</mixed-citation><mixed-citation xml:lang="en">Zhou R., Zhang S., Gu X., Ge Y., Zhong D., Zhou Y., Tang L., Liu X.L., Chen J.F. Adenosine A2A receptor antagonists act at the hyperoxic phase to confer protection against retinopathy. Molecular Medicine. 2018; 24(41): 1–13. doi: 10.1186/s10020-018-0038-1.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Vigano S., Alatzoglou D., Irving M., Ménétrier-Caux C., Caux C., Romero P., Coukos G. Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function. Front. Immunol. 2019; 10: 925. doi: 10.3389/fimmu.2019.00925.</mixed-citation><mixed-citation xml:lang="en">Vigano S., Alatzoglou D., Irving M., Ménétrier-Caux C., Caux C., Romero P., Coukos G. Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function. Front. Immunol. 2019; 10: 925. doi: 10.3389/fimmu.2019.00925.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
